IU School of Medicine researcher Dr. Bryan Schneider is leading a new nationwide clinical trial to improve cure rates for patients with triple-negative breast cancer.
PERSEVERE, a phase 2 clinical trial, is designed to better understand the effectiveness of personalized cancer treatments based on patients’ genetic makeup.
IU School of Medicine Launches New Study to Treat Rare Form of Breast Cancer
